Want to join the conversation?
Biotechnology company $CARA announced positive topline results from its Phase 2a trial of oral CR845 in patients with osteoarthritis of the knee or hip. All tablet strengths were generally well tolerated with no drug-related SAEs. Based on these results, $CARA plans to conduct a larger double-blind, placebo-controlled Phase 2b trial in 2016.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.